CAR T-Cell Immunotherapy Market Overview

The report is titled as ‘CAR T-Cell Immunotherapy Market: Opportunity Analysis and Future Assessment 2020-2028’. An overview of conceptual frameworks, analytical approaches of the CAR T-Cell immunotherapy market is the main objective of the report, which further consists of the market opportunity and insights of the data involved in the making of the respective market. CAR T-Cell immunotherapy market is expected to grow with significant rate in the near future.

The global CAR T-Cell immunotherapy market in 2020 is estimated for more than US$ 584.2 Bn and expected to reach a value of US$ 6,503.1 Bn by 2028 with a significant CAGR of 35.3%.

CAR T-Cell Immunotherapy Market Definition

Cancer has an extensive influence on society across the world as the rates of occurring cancer among the population is surging rapidly. The cancer statistics clearly show the picture of the burden of cancer on society in recent times. As per the recent estimates, far and by the highest risk factor for most kinds of cancer is merely growing older.

A recent study shows that the longer a person lives, the more he is vulnerable to errors to build up. And as a result of which, as time goes by, one is more and more prone to developing any kind of cancer. On top of that, cancer is one of the major causes of casualties all across the globe.

Although on the hopeful prospect, over the past few years, the medical professionals and cancer specialists are more inclined towards the targeted immunotherapies with regard to cancer therapy including CAR-T cell therapies which are increasingly more preferred over chemotherapy, radiation, and surgery. The CAR-T cell immunotherapy mainly spots cancer cells and enhances the immune system of the patient against the tumor.

CAR T-Cell Immunotherapy Market Dynamics

CAR-T or Chimeric antigen receptor cell therapy consists of re-building of white blood cells or WBC of the cancer patient in order to fight off against the disease. The process of CAR-T cell immunotherapy comprises obtaining, re-engineering, and then re-inserting of T-cells of the cancer-affected patient so that the cells multiply and fight off the cancer cells.

The constantly surging count of cancer patients all across the world is majorly expected to boost the growth of the CAR-T cell immunotherapy market in the forthcoming years.

Along with that, the CAR-T cell immunotherapy is considered more effective for blood cancer patients as well as those who have already undergone treatment like chemotherapy. Attributing to such factors, the global CAR-T cell immunotherapy market is projected to elevate higher during the forecast period.

Noticeably, the population across the world are preferring CAR-T cell immunotherapy more than traditional radiation or chemotherapy due to the response failures, which is also contributing to the growing demand of CAR-T cell immunotherapy in the global market.

Owing to which, the global CAR-T cell immunotherapy market is estimated to accelerate further in the near future. Furthermore, the constant advancements in the treatments and therapies to cure the disease is also positively fueling the growth of the global CAR-T cell immunotherapy market in the coming years.

CAR T-Cell Immunotherapy Market Key Players

Some of the key participating players in CAR T-Cell immunotherapy market are

•    AbbVie Inc.

•    Celgene Corporation

•    Kite Pharma

•    Oxford BioMedica

•    Novartis International AG

•    Gilead Sciences, Inc.

•    Pfizer, Inc.

•    Cellectis

•    Bellicum Pharmaceuticals Inc.

•    Mustang Bio

•    CARsgen Therapeutics Ltd.

•    Xyphos

•    Minerva Biotechnologies

•    Adaptimmune

•    Ziopharm Oncology Inc.

CAR T-Cell Immunotherapy Market Segmentation

The CAR T-Cell immunotherapy market is segmented on the basis of type, application, and region.

By Type

•    Monotherapy

•    Combination Therapy

By Application

•    Hematologic Malignancies

•    Solid Malignancies

By Region

•    North America

•    Latin America

•    Europe

•    Asia Pacific

•    Middle East

•    Africa

MMC Overview on CAR T-Cell Immunotherapy Market Report

The non-identical approach of Meridian Market Consultants stands with conceptual methods backed up with the data analysis. The novel market understanding approach makes up the standard of the assessment results that give better opportunity for the customers to put their effort.

A research report on the CAR T-Cell Immunotherapy market by Meridian Market Consultants is an in-depth and extensive study of the market based on the necessary data crunching and statistical analysis. It provides a brief view of the dynamics flowing through the market, which includes the factors that supports market and the factors that are acting as impedance for the growth of the market.

Furthermore, the report includes the various trends and opportunities in the respective market in different regions for a better understanding of readers that helps to analyze the potential of the market.

Factors that are benchmarked while estimating the market

Various factors that are benchmarked while estimating the market growth include (but not restricted to):

•    New product designs and launches

•    Current product compliance

•    Reimbursement

•    Concerns for use of CAR T-Cell Immunotherapy

•    Advantages of CAR T-Cell Immunotherapy over other modalities

Actions taken by the manufacturer and respective regulatory authorities also impact the market growth of the segment. These factors are understood at regional level and in major countries globally for providing regional insights of the product segment in the report. This helps our clients to take informed decision.

A mix of top-down and bottom-up approach is followed to arrive and validate our market value estimations. For a product segment like wherein one/two manufacturer(s) dominates the market, it’s products sales, previous growth rates and market expansion plans are considered to generate market share in the global market.

1.    Global CAR T-Cell Immunotherapy Market Report Overview

1.1.    Introduction

1.2.    Report Description

1.3.    Methodology

2.    Global CAR T-Cell Immunotherapy Market Overview

2.1.    Introduction

2.1.1.    Market Definition

2.1.2.    Market Taxonomy

2.2.    Executive Summary

2.3.    Global CAR T-Cell Immunotherapy Market Snapshot

2.4.    Global CAR T-Cell Immunotherapy Market Size and Forecast, 2020–2028

2.4.1.    Introduction

2.4.2.    Market Value Forecast and Annual Growth Rate (AGR) Comparison (2020–2028)

2.5.    Global CAR T-Cell Immunotherapy Market Dynamics

2.5.1.    Drivers

2.5.2.    Restraints

2.5.3.    Opportunity

2.5.4.    Trends

2.6.    Key Regulations

2.7.    Porter’s Five Forces Model

3.    Global CAR T-Cell Immunotherapy Market, By Type

3.1.    Introduction

3.1.1.    Annual Growth Rate Comparison, By Type

3.1.2.    BPS Analysis, By Type

3.2.    Market Revenue (US$Mn) Forecast, By Type

3.2.1.    Monotherapy

3.2.2.    Combination Therapy

3.3.    Global CAR T-Cell Immunotherapy Market Attractiveness Index, By Type

4.    Global CAR T-Cell Immunotherapy Market, By Application

4.1.    Introduction

4.1.1.    Annual Growth Rate Comparison, By Application

4.1.2.    BPS Analysis, By Application

4.2.    Market Revenue (US$Mn) Forecast, By Application

4.2.1.    Hematologic Malignancies

4.2.2.    Solid Malignancies

4.3.    Global CAR T-Cell Immunotherapy Market Attractiveness Index, By Application

5.    Global CAR T-Cell Immunotherapy Market, By Region

5.1.    Introduction

5.1.1.    Annual Growth Rate Comparison, By Region

5.1.2.    BPS Analysis, By Region

5.2.    Market Revenue (US$Mn) Forecast, By Region

5.2.1.    North America

5.2.2.    Latin America

5.2.3.    Europe

5.2.4.    Asia Pacific

5.2.5.    Middle East

5.2.6.    Africa

5.3.    Global CAR T-Cell Immunotherapy Market Attractiveness Index, By Region

6.    North America CAR T-Cell Immunotherapy Market Analysis and Forecast, 2020–2028

6.1.    Introduction

6.1.1.    Annual Growth Rate Comparison, By Country

6.1.2.    BPS Analysis, By Country

6.2.    Market Revenue (US$Mn) Forecast, By Country

6.2.1.    U.S. CAR T-Cell Immunotherapy Market

6.2.2.    Canada CAR T-Cell Immunotherapy Market

6.3.    North America CAR T-Cell Immunotherapy Market, By Type

6.3.1.    Monotherapy

6.3.2.    Combination Therapy

6.4.    North America CAR T-Cell Immunotherapy Market, By Application

6.4.1.    Hematologic Malignancies

6.4.2.    Solid Malignancies

6.5.    North America CAR T-Cell Immunotherapy Market Attractiveness Index

6.5.1.    By Country

6.5.2.    By Type

6.5.3.    By Application

7.    Latin America CAR T-Cell Immunotherapy Market Analysis and Forecast, 2020–2028

7.1.    Introduction

7.1.1.    Annual Growth Rate Comparison, By Country

7.1.2.    BPS Analysis, By Country

7.2.    Market (US$Mn) Forecast, By Country

7.2.1.    Brazil CAR T-Cell Immunotherapy Market

7.2.2.    Mexico CAR T-Cell Immunotherapy Market

7.2.3.    Argentina CAR T-Cell Immunotherapy Market

7.2.4.    Rest of Latin America CAR T-Cell Immunotherapy Market

7.3.    Latin America CAR T-Cell Immunotherapy Market, By Type

7.3.1.    Monotherapy

7.3.2.    Combination Therapy

7.4.    Latin America CAR T-Cell Immunotherapy Market, By Application

7.4.1.    Hematologic Malignancies

7.4.2.    Solid Malignancies

7.5.    Latin America CAR T-Cell Immunotherapy Market Attractiveness Index

7.5.1.    By Country

7.5.2.    By Type

7.5.3.    By Application

8.    Europe CAR T-Cell Immunotherapy Market Analysis and Forecast, 2020–2028

8.1.    Introduction

8.1.1.    Annual Growth Rate Comparison, By Country

8.1.2.    BPS Analysis, By Country

8.2.    Market (US$Mn) Forecast, By Country

8.2.1.    U.K. CAR T-Cell Immunotherapy Market

8.2.2.    Germany CAR T-Cell Immunotherapy Market

8.2.3.    Italy CAR T-Cell Immunotherapy Market

8.2.4.    France CAR T-Cell Immunotherapy Market

8.2.5.    Spain CAR T-Cell Immunotherapy Market

8.2.6.    Russia CAR T-Cell Immunotherapy Market

8.2.7.    Poland CAR T-Cell Immunotherapy Market

8.2.8.    BENELUX CAR T-Cell Immunotherapy Market

8.2.9.    NORDIC CAR T-Cell Immunotherapy Market

8.2.10.    Rest of Europe CAR T-Cell Immunotherapy Market

8.3.    Europe CAR T-Cell Immunotherapy Market, By Type

8.3.1.    Monotherapy

8.3.2.    Combination Therapy

8.4.    Europe CAR T-Cell Immunotherapy Market, By Application

8.4.1.    Hematologic Malignancies

8.4.2.    Solid Malignancies

8.5.    Europe CAR T-Cell Immunotherapy Market Attractiveness Index

8.5.1.    By Country

8.5.2.    By Type

8.5.3.    By Application

9.    Asia Pacific CAR T-Cell Immunotherapy Market Analysis and Forecast, 2020–2028

9.1.    Introduction

9.1.1.    Annual Growth Rate Comparison, By Country

9.1.2.    BPS Analysis, By Country

9.2.    Market (US$Mn) Forecast, By Country

9.2.1.    China CAR T-Cell Immunotherapy Market

9.2.2.    India CAR T-Cell Immunotherapy Market

9.2.3.    Japan CAR T-Cell Immunotherapy Market

9.2.4.    Australia and New Zealand CAR T-Cell Immunotherapy Market

9.2.5.    South Korea CAR T-Cell Immunotherapy Market

9.2.6.    ASEAN CAR T-Cell Immunotherapy Market

9.2.7.    Rest of Asia Pacific CAR T-Cell Immunotherapy Market

9.3.    Asia Pacific CAR T-Cell Immunotherapy Market, By Type

9.3.1.    Monotherapy

9.3.2.    Combination Therapy

9.4.    Asia Pacific CAR T-Cell Immunotherapy Market, By Application

9.4.1.    Hematologic Malignancies

9.4.2.    Solid Malignancies

9.5.    Asia Pacific CAR T-Cell Immunotherapy Market Attractiveness Index

9.5.1.    By Country

9.5.2.    By Type

9.5.3.    By Application

10.    Middle East CAR T-Cell Immunotherapy Market Analysis and Forecast, 2020–2028

10.1.    Introduction

10.1.1.    Annual Growth Rate Comparison, By Country

10.1.2.    BPS Analysis, By Country

10.2.    Market (US$Mn) Forecast, By Country

10.2.1.    GCC Countries CAR T-Cell Immunotherapy Market

10.2.2.    Israel CAR T-Cell Immunotherapy Market

10.2.3.    Oman CAR T-Cell Immunotherapy Market

10.2.4.    Rest of Middle East CAR T-Cell Immunotherapy Market

10.3.    Middle East CAR T-Cell Immunotherapy Market, By Type

10.3.1.    Monotherapy

10.3.2.    Combination Therapy

10.4.    Middle East CAR T-Cell Immunotherapy Market, By Application

10.4.1.    Hematologic Malignancies

10.4.2.    Solid Malignancies

10.5.    Middle East CAR T-Cell Immunotherapy Market Attractiveness Index

10.5.1.    By Country

10.5.2.    By Type

10.5.3.    By Application

11.    Africa CAR T-Cell Immunotherapy Market Analysis and Forecast, 2020–2028

11.1.    Introduction

11.1.1.    Annual Growth Rate Comparison, By Country

11.1.2.    BPS Analysis, By Country

11.2.    Market (US$Mn) Forecast, By Country

11.2.1.    South Africa CAR T-Cell Immunotherapy Market

11.2.2.    Egypt CAR T-Cell Immunotherapy Market

11.2.3.    North Africa CAR T-Cell Immunotherapy Market

11.2.4.    Rest of Africa CAR T-Cell Immunotherapy Market

11.3.    Africa CAR T-Cell Immunotherapy Market, By Type

11.3.1.    Monotherapy

11.3.2.    Combination Therapy

11.4.    Africa CAR T-Cell Immunotherapy Market, By Application

11.4.1.    Hematologic Malignancies

11.4.2.    Solid Malignancies

11.5.    Africa CAR T-Cell Immunotherapy Market Attractiveness Index

11.5.1.    By Country

11.5.2.    By Type

11.5.3.    By Application

12.    Recommendation

12.1.    Market Strategy

13.    Competitive Landscape

13.1.    Competition Dashboard

13.2.    List and Company Overview of Global Key Players

13.3.    Company Profiles

13.3.1.    AbbVie Inc.

13.3.1.1.    Company Overview

13.3.1.2.    Financial Overview

13.3.1.3.    Type Portfolio

13.3.1.4.    Key Developments

13.3.1.5.    Business Strategies

13.3.2.    Celgene Corporation

13.3.3.    Kite Pharma

13.3.4.    Oxford BioMedica

13.3.5.    Novartis International AG

13.3.6.    Gilead Sciences, Inc.

13.3.7.    Pfizer, Inc.

13.3.8.    Cellectis

13.3.9.    Bellicum Pharmaceuticals Inc.

13.3.10.    Mustang Bio

13.3.11.    CARsgen Therapeutics Ltd.

13.3.12.    Xyphos

13.3.13.    Minerva Biotechnologies

13.3.14.    Adaptimmune

13.3.15.    Ziopharm Oncology Inc.

14.    Acronyms